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Failure of Embryonic Hematopoiesis and
Lethal Hemorrhages in Mouse Embryos Heterozygous
for a Knocked-In Leukemia Gene CBFB–MYH11
Lucio H. Castilla,1,6 Cisca Wijmenga,1,6,7 Qing Wang,4 et al., 1995; Nuchprayoon et al., 1994; Prosser et al.,
1992; Takahashi et al., 1995; Zhang et al., 1994). CBFbTerryl Stacy,4 Nancy A. Speck,4 Michael Eckhaus,3
Miguel Marı´n-Padilla,5 Francis S. Collins,1 associates with the DNA-binding subunits, collectively
called CBFa, and increases their affinities for DNA byAnthony Wynshaw-Boris,2 and Pu P. Liu1
1 Laboratory of Gene Transfer 5- to 10-fold (Ogawa et al., 1993; Wang et al., 1993).
MYH11 codes for the smooth muscle myosin heavy2Laboratory of Genetic Disease Research
National Center for Human Genome Research chain (SMMHC) (Liu et al., 1993; Matsuoka et al., 1993).
One fusion generated by chromosome 16 inversion3Veterinary Resources Program
National Center for Research Resources combines, in frame, most of the CBFB coding region
with the 39 half of MYH11 that codes for the tail ofNational Institutes of Health
Bethesda, Maryland 20892 SMMHC. This CBFB–MYH11 fusion gene is believed to
play an active role in leukemogenesis. The reciprocal4Department of Biochemistry
5Department of Pathology fusion generates a gene encoding the head region of
myosin and the last 22 amino acids of CBFb; however,Dartmouth Medical School
Hanover, New Hampshire 03755 this reciprocal fusion gene is not transcribed at detect-
able levels in leukemic cells and is deleted in some
patients (Liu et al., 1993; Marlton et al., 1995).
CBFb is encoded by a unique gene in both the humanSummary
and the mouse genomes, whereas CBFa subunits are
encoded by three related genes. One of the three CBFAThe fusion oncogene CBFB–MYH11 is generated by
genes, CBFA2, also known as AML1 or PEBP2aB, isa chromosome 16 inversion in human acute myeloid
located on chromosome 21 and is itself rearranged inleukemia subtype M4Eo. Mouse embryonic stem (ES)
certain leukemias, including t(8;21) in acute myeloid leu-cells heterozygous for this oncogene were generated
kemia subtype M2, t(3;21) in therapy-related leukemiaby inserting part of the human MYH11 cDNA into the
and myelodysplasia, and t(12;21) in childhood acutemouse Cbfb gene through homologous recombination
lymphocytic leukemia (Golub et al., 1995; Miyoshi et al.,(knock-in). Chimeric mice were leukemia free, but the
1991; Nucifora et al., 1993, 1994; Romana et al., 1995).ES cells with the knocked-in Cbfb–MYH11 gene did
Together with inversion 16, these chromosome changesnot contribute to their hematopoietic tissues. Mouse
make alterations of CBFB and CBFA2 the most frequentembryos heterozygous for Cbfb–MYH11 lacked defini-
genetic rearrangements in human leukemias.tive hematopoiesis and developed multiple fatal hem-
Both the Cbfa2 and Cbfb genes are required for fetalorrhages around embryonic day 12.5. This phenotype
liver hematopoiesis, as demonstrated by the homozy-is very similar to that resulting from homozygous dele-
gous disruption of either of these two genes (Okuda ettions of either Cbfb or Cbfa2 (AML1), consistent with a
al., 1996; Wang et al., 1996a; Wang et al., 1996b [thisdominant negative function of the Cbfb–MYH11 fusion
issue of Cell]). Moreover, homozygous disruption of ei-oncogene. An impairment of primitive hematopoiesis
was also observed, however, suggesting a possible ther Cbfa2 or Cbfb results in embryonic lethality be-
additional function of Cbfb–MYH11. tween days 11.5 and 13.5 of gestation (E11.5–13.5) ow-
ing to hemorrhages in the central nervous system (CNS).
The associated cellular necrosis and perivascularIntroduction
edema in the CNS may contribute to development of
the hemorrhages. In vitro culture of yolk sac and fetalInversion of chromosome 16 is a consistent finding in
liver cells from Cbfa22/2 and Cbfb2/2 embryos results inpatients with acute myeloid leukemia subtype M4Eo (Le
no myeloid or erythroid colonies. Furthermore, Cbfa22/2Beau et al., 1983). Two chimeric genes (CBFB–MYH11
or Cbfb2/2 embryonic stem (ES) cells lack myeloid andand MYH11–CBFB) are generated by this inversion, join-
erythroid differentiation in culture and fail to contributeing the CBFB gene on 16q with the MYH11 gene on 16p
to hematopoiesis in chimeric mice (Okuda et al., 1996;(Liu et al., 1993). CBFB encodes the non-DNA-binding
Wang et al., 1996a, 1996b; T. S., J. D. Miller, and N. A. S.,subunit (b subunit) of the core-binding factor (CBF, also
unpublished data). These results support the hypothesisnamed PEBP2) (Bae et al., 1993; Ogawa et al., 1993;
that Cbfa2 and Cbfb function through the same regula-Wang et al., 1993). CBF is a heterodimeric transcription
tory pathway. More importantly, it is clear that their func-factor involved in the expression regulation of genes
tions are indispensable for definitive hematopoiesis andimportant in hematopoiesis, such as granulocyte/mac-
the integrity of embryonic blood circulation.rophage colony-stimulating factor (GM-CSF), interleu-
The protein encoded by the chromosome 16 inversionkin-3 (IL3), myeloperoxidase (MPO), colony-stimulating
fusion gene (named CBFb–SMMHC) retains its ability tofactor-1 (CSF-1) receptor, T cell receptor a (TCRa), and
bind CBFa and to participate in the formation of protein–TCRb (Cameron et al., 1994; Frank et al., 1995; Giese
DNA complexes (Liu et al., 1994). It can also form homo-
multimers, in contrast with the monomeric CBFb, pre-6 These authors contributed equally to this study.
sumably through the coiled-coil domain of the myosin7 Present address: Department of Human Genetics, Utrecht Univer-
sity, 3508 TA Utrecht, The Netherlands. tail (Liu et al., 1994; Wijmenga et al., 1996). We have
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Figure 1. Targeting of the Mouse Cbfb Allele with the Cbfb–MYH11 Fusion Construct
(A) Wild-type Cbfb exon 5 sequence, compared with the respective sequence for human CBFB–MYH11. Sequences present in the targeting
construct are capitalized. The StuI site used is also labeled. The naturally occurring alternative splicing site within exon 5 is indicated by a
vertical arrow.
(B) Targeting strategy used to replace exon 5 of the wild-type Cbfb gene with the Cbfb–MYH11 fusion construct. Locations of probes X2 and
0.2C and the sizes of NcoI fragments detected by these two probes are indicated.
(C) Southern blot analysis of NcoI-digested DNA from targeted (ES 02, ES 25, ES 55, ES 89, and ES 94) and non-targeted (TC 1) cells, probed
with 0.2C. The 15.7 kb band corresponds to the wild-type Cbfb allele and the 6.8 kb band corresponds to the correctly knocked-in allele.
also demonstrated that the CBFb–SMMHC fusion pro- Results
tein can interfere with the transactivation function of the
normal CBF heterodimer (Liu et al., 1994). Generation of a Targeted Fusion between Mouse
Cbfb and a Human MYH11 cDNA FragmentTo understand better themechanism by which CBFB–
MYH11 contributes to leukemogenesis, we introduced The Cbfb targeting vector contained the murine Cbfb
exon 5 fused to the 39 end sequence of a human CBFB–the CBFB–MYH11 gene into mouse genome and studied
the effect of this fusion gene in vivo. We created the MYH11 cDNA (Liu et al., 1994) through a common StuI
site in exon 5, located 66 bp upstream of the fusion pointCBFB–MYH11 fusion oncogene in mouse ES cells by
inserting the 39 part of the human MYH11 cDNA into (Figure 1A). The CBFB–MYH11 cDNA used to create the
knock-in allele represents the fusion resulting from thethe end of exon 5 of the mouse Cbfb gene through
homologous recombination (denoted a “knock-in”). This most common type of chromosome 16 inversion (type
A in Liu et al., 1995). A polyadenylation signal sequenceway, a half genomic (Cbfb), half cDNA (MYH11) fusion
gene was created, which resulted in the production of from the bovine growth hormone gene was placed at
the 39 end of MYH11. The Cbfb exon 5–MYH11 fusiona Cbfb–SMMHC fusion protein, mimicking that found in
human leukemia cells, under the control of the Cbfb sequence was flanked by sequences from introns 4 and
5 of the mouse Cbfb gene. A PGK–neo gene was insertedpromoter. We demonstrate that Cbfb–SMMHC domi-
nantly suppresses the normal function of Cbf gene prod- in intron 5 for positive selection, and the thymidine ki-
nase gene was used for negative selection (Figure 1B).ucts, and blocks the differentiation of hematopoietic
stem cells. Such effects of Cbfb–SMMHC may be an The knock-in construct was introduced into TC 1 ES
cells (from mouse strain 129/SvEv; see Deng et al., 1996)important step in the leukemogenic process involving
the inversion 16 fusion gene CBFB–MYH11. by electroporation, and cell clones were selected by
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40% to more than 90%, based on coat color. Southern
blot hybridization of tail DNA confirmed the presence
of cells derived from the targeted ES cells (Figure 2A).
The chimeric mice remained healthy 7 months after
birth, with no signs of leukemia or any disturbances of
hematopoietic growth and differentiation,based ontheir
blood cell counts, hematocrits, and white blood cell
differentials (data not shown). However, ES cell–derived
peripheral blood cellswere undetectable in these chime-
ras. Primers specific for the neo gene were used for
polymerase chain reaction (PCR) with DNA isolated from
peripheral blood of all the chimeras. None of the chime-
ras containedneo-positive peripheral blood cells (Figure
2B). This result was confirmed by glucose-6-phosphate
isomerase (GPI) isozyme assay. Cells in chimeric mice
originating from the injected TC 1 ES cells (129/Sv)
should contain the Ia isoform of GPI, whereas cells de-
rived from the C57BL/6 blastocysts should contain the
Ib isoform of GPI. As shown in Figure 2C, kidney, skeletal
muscle, and heart from all four chimeric mice studied
contained both the GPI-Ia and GPI-Ib isoforms (the inten-
sity of the GPI-Ia band in the heart lanes was variable
among the four chimeras), indicating that ES cells con-
tributed significantly to these non-hematopoietic tis-
sues. On theother hand, peripheral blood, bone marrow,
and thymus contained exclusively the Ib isoform ofFigure 2. Contribution of ES Cell Lineage in Chimeric Animals
C57BL/6, while spleen and liver contained mostly the Ib
(A) Southern blot analysis of tail genomic DNA. DNA was digested
isoform with none or a small quantity of the GPI-Ia iso-with NcoI and probed with 0.2C. The intensity variation of the
form. Thus, the hematopoietic tissues of these chimericknocked-in 6.8 kb band reflects the variable contribution of the ES
lineage to the seven chimeras (lanes A–G). Controls are the ES cell mice derived entirely from the host C57BL/6 blasto-
clone with the knocked-in Cbfb–MYH11 gene (ES 55) and the non- cytes. These results suggest that there is a selective
targeted ES cells (TC 1). inability of the Cbfb–MYH11 heterozygous ES cells to
(B) PCR analysis of the contribution of ES cell lineages to peripheral contribute to hematopoietic organs. These results also
blood cells. The presence of the knocked-in gene was tested using
explain why the leukemogenic potential of the Cbfb–neo-specific primers, which should produce a product of 431 bp in
MYH11 fusion gene was not fully manifested in the chi-DNA containing the knocked-in gene. The integrity of DNA samples
was tested in parallel using Trp53-specific primers, which should meric mice.
produce a product of 460 bp. PCR products from peripheral blood
genomic DNA of chimeric animals are shown (lanes A–G). Controls
include DNA from pheripheral blood of Black Swiss strain (lane bs) Embryos Heterozygous for the Cbfb–MYH11
and from tail DNA of the chimeric animal G (lane tG). nt, no template Allele Die In Utero
control; MW, molecular weight marker.
We attempted to generate mice heterozygous for the(C) GPI isomerase assay. GPI isomerase assaywith proteins isolated
knocked-in Cbfb–MYH11 gene by mating the chimericfrom one chimeric mouse is shown. Tissues used included kidney
mice with wild-type female mice of three different strains(K),peripheral blood (P), bone marrow (B),spleen (S), liver (L), thymus
(T), heart (H), and skeletal muscle (M). Control samples included (C57BL/6, NIH Black Swiss, and 129/Sv). Chimeric mice
kidney protein extracts from animals of C57BL/6 (with isoform IbIb) generated with two independent ES cell clones (ES 55
or 129/Sv (with isoform IaIa) background. and ES 94) had successful germline transmission, as
indicated by the high percentage of pups with agouti
coat color. However, none of these liveborn agouti pups
growth in media containing G418/FIAU. Drug-resistant inherited the Cbfb–MYH11 fusion gene (Table 1).
ES clones were screened by Southern blot hybridization When embryos at different developmental stages
for homologous recombination of the Cbfb–MYH11 fu- were examined, it was discovered that Cbfb–MYH11
sion sequence into one of the endogenous Cbfb alleles. heterozygous embryos died in utero between embryonic
We identified 5 of 120 Neo/FIAU-resistant ES clones to days 11.5 (E11.5) and 13.5 (E13.5; Table 1). At E11.5, all
have the correct insertion (Figure 1C), and two clones embryos appeared normal; z50% were heterozygous
(ES 55 and ES 94) were used for further studies. for Cbfb–MYH11, as detected by PCR with yolk sac
DNA. Embryos heterozygous for the Cbfb–MYH11 allele
looked identical to wild-type embryos in size and devel-ES Cells Heterozygous for the Cbfb–MYH11
Allele Do Not Contribute to Hematopoietic opmental stage, and no abnormalities were observed
histologically (data not shown). Starting at E12.0, Cbfb–Tissues in Chimeric Mice
Two independently targetedES cellclones were injected MYH11 heterozygous embryos developed multiple hem-
orrhages, most frequently in the CNS. By E12.5, all theinto C57BL/6 blastocysts, and chimeric mice were gen-
erated with varying degrees of chimerism, ranging from Cbfb–MYH11 heterozygous embryos had hemorrhages
Cell
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Table 1. Genotype and Phenotype of Embryos Derived from Crosses between Cbfb–MYH11 Transmitting Chimeric Males and Normal
Females
Genotype Phenotype of 1/KI
Stage Total Number (Litters) 1/1 1/KI Hemorrhage Alive
E 9.5 37 (4) 18 19 0 19
E 10.5 25 (3) 12 13 0 13
E 11.5 34 (3) 17 17 0 17
E 12.5 60 (7) 29 31 30 15
E 13.5 20 (2) 12 8 8a 0
E 14.5 23 (3) 11 12 12a 0
After birth 81 (16) 81 0 — —
a All embryos in process of reabsorption.
(Figure 3A) except one (Table 1), but about half of them the ganglia of the VII and VIII cranial nerves (Figures 3A
and 3C) and dorsal root ganglia, as well as in regionswere still alive, based on continued heart beats (Table
1). By E13.5, all theCbfb–MYH11 heterozygous embryos adjacent to somites (Figure 3A). Several embryos had
massive hemorrhages in the pericardial and peritonealwere dead, presumably from massive hemorrhages.
There were no developmental defects nor delays in de- cavities, the origin of which has not been clearly defined
(Figure 3D). We also noted multifocal cellular degenera-velopment up to this time.
Hemorrhages were found most frequently in the peri- tion or apoptosis in the areas prone to hemorrhage
(Figure 3E), as reported for Cbfa2 and Cbfb knock-outventricular regions of the striatum, pons, medulla, and
spinal cord (Figures 3A and 3B). Extravascular blood embryos (Wang et al., 1996a, 1996b). Therefore, hemor-
rhages in Cbfb–MYH11 heterozygous embryos ap-often extended through the ependyma, leading to the
accumulation of large amounts of blood in the ventricles peared to be associated with areas of apoptosis, as has
been described for Cbfa2 and Cbfb knock-out embryosof the developing brain and the spinal cord (Figure 3A).
Intraparenchymal hemorrhages were also frequent at (Wang et al., 1996a, 1996b).
Figure 3. Comparison of Wild-Type and Cbfb–MYH11 Heterozygous Embryos
(A) Gross view of whole embryos at E12.5. The embryo on the left is wild type and the one on the right is heterozygous for the knocked-in
Cbfb–MYH11 gene. Blood accumulation is visible in the CNS ventricles (1) and spinal cord (2). Interstitial hemorrhages are noted in the region
for the VIII cranial nerve (black arrow) and around a dorsal ganglion (white arrow). The areas for the livers are marked by asterisks. The picture
was taken with a Nikon SMZ-U dissecting microscope camera with zoom setting at 0.75.
(B) Striatal hemorrhage (arrow) of an E12.5 Cbfb–MYH11 heterozygous embryo (original magnification, 3160).
(C) Hemorrhage within an VIII cranial nerve ganglion (left) with an intact V cranial nerve ganglion (right) of an E12.5 Cbfb–MYH11 heterozygous
embryo (original magnification, 3100).
(D) Pericardial hemorrhage (original magnification, 3100). The blood in the pericardial cavity is indicated by arrows.
(E) Cellular necrosis within VII nerve and medulla (original magnification, 3250). Representative necrotic cells are indicated by arrows.
(F) and (G) Histologic sections of the fetal livers (originalmagnification, 3400). 1/KI: Cbfb–MYH11 heterozygous; 1/1: wild type. The megakaryo-
cytes in the wild-type liver are indicated by arrows. Panels (B)–(G) were H and E stained.
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targeted insertion of the MYH11 cDNA resulted in the
creation of a Cbfb–MYH11 fusion gene and the produc-
tion of a fusion transcript and a fusion protein identical
to those found in leukemic cells with a chromosome 16
inversion.
Lack of Fetal Liver Hematopoiesis
The livers of the E11.5–13.5 Cbfb–MYH11 heterozygous
embryos were very pale and small in size, compared
with livers from wild-type embryos of the same gesta-
tional ages (see Figure 3A). Histologically, livers of the
Cbfb–MYH11 heterozygous embryos contained very
few, if any, erythropoietic cells, and no identifiable meg-
akaryocytes (see Figure 3F). Only circulating, yolk sac–
derived primitive erythrocytes were observed in liver
sinusoids, while hepatic cords were devoid of definitive
hematopoietic cells. This was in sharp contrast with the
wild-type embryo livers, in which numerous hematopoi-
etic cells at different developmental stages were present
throughout the hepatic cords (see Figure 3G). Notice-
ably, megakaryocyteswere evident in the wild-type liver;
at least one can be seen in every field at high magnifica-
Figure 4. Expression of the Knocked-In Cbfb–MYH11 Gene in Em- tion (4003; see arrows in Figure 3G).
bryos
The lack of hematopoiesis in the liver was further
(A) PCR analysis of reverse-transcribed total RNA from two wild-
supported by examining cytocentrifugation prepara-type (1/1) embryos and three embryos heterozygous (1/KI) for the
tions of fetal liver cells of E12.5 embryos. There wereCbfb–MYH11 fusion gene with two primers at the junction of exon
many more immature erythroblasts in livers of the wild-3–4 of Cbfb and within MYH11 cDNA, respectively.
(B) Western blot analysis of E12.5 embryos (1/1 for wild type and type embryos than in livers from the Cbfb–MYH11 het-
1/KI for Cbfb–MYH11 heterozygotes) using a mouse monoclonal erozygous embryos (data not shown).
antibody (b141.2) specific for Cbfb. The calculated molecular weight
of Cbfb is 22 kD, and that of the Cbfb–SMMHC fusion protein is
The Cbfb–MYH11 Gene Blocks Definitive71 kD.
Hematopoiesis In Vitro
We also performed in vitro colony-forming assays to
Expression of Cbfb–MYH11 Fusion Gene assess the capacity of definitive hematopoiesis with fe-
Products from the Knocked-In Allele tal liver, yolk sac, and ES cells. For wild-type embryos,
The expression of the targeted allele in the embryos was E11.5–E12.5 fetal liver cells and E10.5 yolk sac cells
examined by reverse transcriptase–polymerase chain proliferated and differentiated in methylcellulose cul-
reaction (RT–PCR) and Western blot analysis using RNA tures under conditions that support definitive hemato-
and proteins isolated from embryos. RT–PCR was con- poiesis, and many hematopoietic colonies were formed
ducted with a primer at the junction of exons 3 and 4 (Table 2). In comparison, fetal liver and yolk sac cells
of Cbfb and another primer from the MYH11 cDNA,using isolated from Cbfb–MYH11 heterozygous littermates
RNA samples from E12.5 wild-type embryos and em- had a highly reduced capacity toproliferate and differen-
bryos heterozygous for the knocked-in gene. A cDNA tiate in vitro, as the number of colonies of myeloid lin-
fragment of the expected size (415 bp) for the Cbfb– eage in the culture was about 0%–1% of the wild type
MYH11 fusion transcript was observed only with RNA (Table 2). Initially, we observed very few erythroid cell–
of embryos heterozygous for Cbfb–MYH11 (Figure 4A). containing colonies (CFU-E) from yolk sac and fetal liver
By Western blotting, proteins of the expected size (71 cells of wild-type embryos. The numbers of erythroid
kD) for the Cbfb–SMMHC fusion protein were detected cell–containing colonies of wild-type embryos differed
in E12.5 embryos heterozygous for the knocked-in significantly from those of the Cbfb–MYH11 heterozy-
Cbfb–MYH11 gene (Figure 4B), using a monoclonal anti- gous embryos by statistical analysis (Table 2), but the
body (b141.2) specific for Cbfb (Wang et al., 1996b). differences were far less than those for the myeloid
The Cbfb–SMMHC fusion protein migrated as a doublet, colonies. We learned later that there is not enough eryth-
which could reflect post-translational modifications of ropoietin in the media (MethoCult M3430, StemCell
a portion of the fusion proteins. In addition, the wild- Technologies, Inc.) to support growth of erythroid cells.
type Cbfb protein was detected in both wild-type and When additional erythropoietin was added to the cul-
Cbfb–MYH11 heterozygous embryos. Western blot de- tures, many erythroid lineage colonies were produced
tection using serial dilutions of the proteins indicated from wild-type fetal liver and nonefrom the Cbfb–MYH11
that Cbfb–SMMHC protein was present in these em- heterozygous fetal liver (E12.0 Liver, Table 2). Therefore,
bryos at a relatively lower level (<2-fold difference) than the failure of definitive hematopoiesis in the Cbfb–
the wild-type Cbfb (presuming equal transfer of both MYH11 heterozygous embryos is panblastic. Moreover,
proteins and equal affinity of the antibody to both pro- ES cells of two independent knock-in clones used for
teins) (data not shown). Taken together, the results of blastocyst injection had a similar defect in their ability
to form secondary hematopoietic colonies comparedRT–PCR and Western blot analyses confirmed that the
Cell
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Table 2. In Vitro Differentiation of Fetal Hematopoietic Lineage
Organ of Origin Age Genotype CFU-GMb CFU-Eb CFU-GEMMb Embryos Analyzed
Yolk sac E 10.5 1/1 128.8 6 35.9 2.1 6 2.0 9.8 6 7.2 8
1/KI 1.2 6 1.5 0 0 9
(p , 0.01) (p , 0.01) (p , 0.01)
Liver E 11.5 1/1 113.5 6 47.3 3.5 6 1.73 3.0 6 1.15 4
1/KI 0.2 6 0.3 0 0 10
(p , 0.01) (p , 0.05) (p , 0.05)
Livera E 12.0 1/1 47.0 6 13.5 68.8 6 15.7 9.2 6 2.55 5
1/KI 0 0 0 4
(p , 0.01) (p , 0.01) (p , 0.01)
Liver E 12.5 1/1 98.5 6 27.3 2.0 6 2.7 1.8 6 1.6 10
1/KI 3.2 6 2.2 1.5 6 1.3 0.5 6 0.5 4
(p , 0.01) (NS) (p , 0.05)
a Additional erythropoietin was added.
b Mean 6 standard deviation per 10,000 cells plated.
with the original TC 1 ES cells (data not shown). These to the Cbfb–MYH11 fusion gene is sufficient to block
definitive hematopoiesis, equivalent to the effect of ho-in vitro colony-forming assays provided supporting evi-
dence that converting one allele of the murine Cbfb gene mozygous deletions of Cbfb and Cbfa2.
Figure 5. Differences in Maturation of Yolk Sac–Derived Erythroblasts between Cbfb–MYH11 Heterozygous (1/KI) and Wild-Type Embryos
(1/1)
(A) and (B) Wright–Giemsa stained cytocentrifuge preparations of peripheral blood cells from E12.5 embryos (original magnification, 3400).
(C) and (D) Same preparations from E10.0 embryos (original magnification, 3400).
(E) and (F) From E11.5 embryos (original magnification, 3400).
(G) Graphic presentation of the maturation differences among peripheral blood cells in Cbfb–MYH11 heterozygous embryos (KI), wild-type
embryos (WT), and Cbfb2/2 embryos (KO) at E12.5. Four embryos were analyzed for each genotype and 500 peripheral blood cells were
differentially counted for each embryo. The plotted lines represent the means, and the error bars are standard deviations. er1: rubriblast; er2:
prorubricyte; er3: rubricyte; er4: metarubricyte (yolk sac–derived mature erythrocyte); er5: fetal liver–derived erythrocyte. (The color photo of
representative erythrocytes at the bottom of [G] is modified from Figure 1 from “The Morphology of Blood Cells,” a publication of Abbott
Laboratories [Diggs et al., 1954]. This reproduction has been granted with approval of Abbott Laboratories, all rights reserved by Abbott
Laboratories).
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Impairment of Maturation of Yolk resulting from the Cbfb–MYH11 knock-in allele is strik-
Sac–Derived Erythroblasts ingly similar to that associated with homozygous disrup-
In peripheral blood, we noticed a large number of circu- tion of the Cbfa2 and Cbfb genes. Although it was pre-
lating erythroblasts in the Cbfb–MYH11 heterozygous sumed that the CBFB–MYH11 fusion gene is dominant,
embryos at E12.5 (Figure 5A). The vast majority of the since only one of the two sets of CBFB and MYH11
circulating blood cells from wild-type (Figure 5B) and genes is disrupted by the chromosome 16 inversion in
Cbfb2/2 embryos (data not shown, see Figure 4A in Wang leukemic cells, our results unequivocally demonstrate
et al., 1996b) were the mature nucleated erythrocytes (or that CBFB–MYH11 behaves in a dominant fashion. The
metarubricytes), derived from the yolk sac. Enucleated similarity of the phenotypes associated with Cbfa22/2,
erythrocytes, derived from definitive erythropoiesis in Cbfb2/2, and Cbfb–MYH11 mutations strongly suggests
the fetal liver, were also frequent in the peripheral blood that the Cbfb–SMMHC protein acts in a dominant nega-
of the wild-type embryos, but were rare in the blood of tive manner to block wild-type Cbf function.
Cbfb2/2 embryos. Occasionally, immature erythroblasts, Although the striking similarity of the phenotypes as-
also called rubriblasts, prorubricytes, and rubricytes, sociated with heterozygosity of the Cbfb–MYH11 fusion
could be seen in the blood of these two types of em- gene and homozygous disruption of either Cbfa2or Cbfb
bryos. In contrast, the peripheral blood of the Cbfb– suggests a dominant negative role for Cbfb–MYH11, at
MYH11 heterozygous embryos contained many imma- least during embryonic development, exactly how the
ture erythroblasts (Figure 5A). As shown in Figure 5G, Cbfb–MYH11 gene product negatively affects Cbfb and
more than 78% of circulating cells in the E12.5 Cbfb– Cbfa2 function is unclear. We previously showed that
MYH11 heterozygous embryos were immature erythro- CBFb–SMMHC can form high molecular weight multi-
blasts, whereas 80% of the cells in Cbfb2/2 embryos mers (Liu et al., 1994; Wijmenga et al., 1996). One possi-
and 87% in wild-type embryos were mature nucleated ble mechanism by which Cbfb–SMMHC transdomi-
primitive erythrocytes. nantly interferes with CBF function might be through the
The circulating immature erythroblasts in the E12.5 assembly of Cbfb–SMMHC multimers that trap Cbfa in
embryos heterozygous for Cbfb–MYH11 were most non-functional complexes, thus reducing the effective
likely derived from the yolk sac, and reflected a delay
Cbfa concentration in cells. Wang et al. (1996b) suggest
or partial blockage of maturation of the primitive erythro-
that Cbfa2 is limiting in hematopoietic progenitor cells
blasts. At E10.0, the circulating blood of both Cbfb–
or pluripotent stem cells; thus, modest decreases in the
MYH11 heterozygous and wild-type embryos consisted
cellular Cbfa2 concentration could be sufficient to blockalmost exclusively of rubriblasts (Figures 5C and 5D),
hematopoiesis (Wang et al., 1996b). Another possible
which were released into circulation from the yolk sac
mechanism for transdominant interference is that Cbfb–to continue proliferation and maturation. There were no
SMMHC:Cbfa2 multimers might assemble on CBF tar-significant differences between the wild-type and the
get sequences and block transcription. This could in-Cbfb–MYH11 heterozygous embryos at this stage, indi-
volve direct inhibition of transcription mediated bycating that the initiation of primitive hematopoiesis was
interaction of Cbfb–SMMHC with general transcriptionapparently normal in embryos heterozygous for Cbfb–
factors assembled at the promoter. Alternatively, CBFMYH11. This was supported by histological examina-
complexes containing Cbfb–SMMHC multimers couldtions of yolk sacs from the Cbfb–MYH11 heterozygous
interfere with binding of other transcription factors toembryos, which revealed no abnormalities (data not
adjacent sites on promoters or enhancers of CBF targetshown). At E11.5, embryonic blood from both wild-type
genes. The CBFb–SMMHC fusion protein is consider-and Cbfb–MYH11 heterozygous embryos contained a
ably larger than thewild-type CBFb protein(71 kD versusspectrum of rubriblasts, prorubricytes, and rubricytes,
22 kD), and could conceivably occupy a much largerreflecting the ongoing maturation process (Figures 5E
region on DNA, especially in its multimeric form. Sinceand 5F). Further maturation of primitive erythrocytes
CBF has been shown to cooperate with transcriptionbetween E11.5 and E12.5 was significantly impaired in
factors such as ets-1, c-Myb, and CCAAT enhancer–the embryos heterozygous for Cbfb–MYH11, resulting
binding protein (C/EBP) to activate transcription (Giesein the accumulation of a large number of immature eryth-
et al.,1995; Hernandez-Munain and Krangel,1994, 1995;roblasts in the circulation. This defect was not detected
Sun et al., 1995; Wotton et al., 1994; Zaiman et al., 1995;in the embryos with homozygous deletions of Cbfa2 and
Zhang et al., 1996), Cbfb–SMMHC complexes might in-Cbfb genes; therefore, it suggests a gain of function of
terfere with the recruitment of essential CBF partnerthe Cbfb–MYH11 fusion gene.
proteins to the promoter. The end result of the latter
mechanism of transdominant interference could becon-Discussion
text dependent. This is consistent with the observation
that transcription from some enhancers (e.g., MMLV)The CBFA2 and CBFB genes encode subunits of the
was suppressed, while transcription from other en-heterodimeric CBF complex. Both genes are required
hancers (RSV) was moderately stimulated by the CBFB–for fetal liver hematopoiesis and are disrupted in a large
MYH11 gene in transient transfection assays (Liu et al.,percentage of human leukemias by chromosomal trans-
1994; P. P. L., unpublished data).locations. Here, we show that mice heterozygous for a
A defect in primitivehematopoiesis was also observedCbfb–MYH11 knock-in allele, which mimics the allele
in Cbfb–MYH11 heterozygous embryos that was not ap-generated by inversion of chromosome 16 associated
parent in Cbfb2/2 and Cbfa22/2 embryos, suggesting thatwith acute myeloid leukemia subtype M4Eo, die in mid-
transdominant interference by the Cbfb–SMMHC fusiongestation from extensive hemorrhages and have se-
verely impaired fetal liver hematopoiesis. The phenotype protein involves more than simple loss of Cbfa2 or Cbfb
Cell
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function. It is not clear whether the Cbfb–MYH11 allele to the development of hematopoietic malignancies,
probably requiring a second mutation, cannot be ad-disrupts an entirely new pathway (primitive erythropoie-
sis) not normally regulated by CBF, or whether in fact dressed in this system, since the embryos die prema-
turely as a consequence of a separate defect. The ab-a minor impairment of yolk sac hematopoiesis also oc-
curred in Cbfa2- and Cbfb-deficient embryos that was sence of leukemia in Cbfb–MYH11 chimeric mice may
suggest that a second step is required. Future experi-too subtle to detect by histological methods. In either
case, the interference mechanism discussed above mental designs that result in the rescue of the embryonic
lethality of the Cbfb–MYH11 gene or the generation ofcould explain why primitive erythropoiesis does not re-
quire CBF but can be disrupted by a transdominant the Cbfb–MYH11 fusion gene or gene product only after
birth should lead to the test of the full leukemogenicnegative derivative of CBF. We hypothesize that certain
genes required for primitive hematopoiesis contain potential of this important leukemia-specific fusion
gene.binding sites for CBF but that normal CBF is not abso-
lutely required for transcription from these genes, and
may in fact contribute very little to their expression. If Experimental Procedures
this were the case, then loss of CBF function would
ES Cell Targetinghave little or no effect on primitive erythropoiesis. On
The targeting construct was assembled in the plasmid vector pPNT,the other hand, a Cbfb–SMMHC protein bound to these
which included a thymidine kinase gene expressed from a PGKsame sites in genes required for primitive erythropoiesis
promoter (PGK–tk) for positive selection (Deng et al., 1996). A 3.5
might actively interfere with the assembly of other nec- kb KpnI–StuI mouse genomic clone (strain 129/Sv), including Cbfb
essary transcription factors, resulting in a more pro- intron 4 and the first 25 bp of exon 5, was ligated to the StuI site
found block in primitive erythropoiesis than simple loss of a 1.5 kb StuI–NotI human CBFB–MYH11 cDNA clone, which in-
cluded the last 66 bp of CBFB exon 5 and the 39 MYH11 cDNA. A 300of CBF function. Candidate transcription factors, whose
bp fragment containing the bovine growth hormone polyadenylationfunction may have been interfered with by Cbfb–
signal (BGH pA) from the pRC/CMV vector (Invitrogen, San Diego,SMMHC, include SCL/tal-1, LMO2/rbtn2, GATA-1, and
CA) was added downstream of the 1.5 kb cDNA fragment. The
GATA-2. All of them have been shown to play important PGKneo was excised from the pPNT vector and ligated downstream
roles in normal primitive hematopoiesis (Pevny et al., of BGHpA. A 4.7 kb mouse genomic clone of Cbfb intron 5 (strain
1991; Robb et al., 1995; Shivdasani et al., 1995; Tsai et 129/Sv) was ligated to the 39 end of the PGKneo fragment. The
targeting constructwas linearized ata unique NotI site, and transfec-al., 1994; Warren et al., 1994; Weiss et al., 1994). Finally,
tions into TC 1 ES cells were performed as described (Deng et al.,this blockage of primitive hematopoiesis may reflect a
1996). To screen for ES cells targeted by homologous recombina-new function of Cbfb–SMMHC, which is unrelated to the
tion, Southern blot analysis of genomic DNA from G418/FIAU-resis-
CBF pathway. Additional studies of this Cbfb–MYH11 tant ES colonies was performed. The DNA was digested with NcoI,
knock-in mouse model are needed to understand the and the blotted DNA was hybridized with probes, one internal to
mechanisms of the Cbfb–MYH11 fusion gene function the targeting DNA fragment (probe X2) and the other, external (probe
0.2C) (Figure 1B). NcoI digestion generates a 15.7 kb band from theduring embryonic hematopoiesis.
endogenous wild-type Cbfb allele that is detected with both probesThe strategy described here is potentially a very effec-
X2 and 0.2C, while the correctly targeted Cbfb–MYH11 allele gener-tive approach for the study of other fusion genes associ-
ates an additional 10 kb band with probe X2 and a 6.8 kb band with
ated with chromosome translocations in cancers, since probe 0.2C. Two targeted ES cells (ES 55 and ES 94) heterozygous
it is simple and generates fusion genes under thecontrol for the knocked-in gene were injected into C57BL/6-derived blasto-
of endogenous promoters. A very different phenotype, cysts. Chimeric mice for Cbfb–MYH11 fusion gene were crossed
with NIH Black Swiss, C57BL/6, and 129/Sv females for furtherhowever, was obtained from the Cbfb–MYH11 knock-
embryo analysis.in compared with the recently reported MLL–AF9 knock-
in, which led to the development of leukemias in chime-
Hematological Analysisric mice (Corral et al., 1996). At least one of the reasons
Peripheral blood was collected from the retroorbital sinus of chime-for the absence of leukemia in Cbfb–MYH11 chimeric
ric animals into 50 ml heparinized capillary tubes (Thomas Scientific,mice might be the severe defects of embryonic hemato-
Swedesboro, NJ). White and red blood cell counts were determined
poiesis. Such defects are likely responsible for the ab- on a Coulter ZM counter (Coulter Electronics, Hialeah, FL). Differen-
sence of Cbfb–MYH111 hematopoietic cells in chimeras, tial counts were determined by examination of blood smears from
each chimeric animal stained with Wright–Giemsa stain.thus preventing the expression of the leukemogenic po-
tential of Cbfb–MYH11 inadult mice. However, theCbfb–
MYH11 knock-in model presented here does provide Genotype Analysis
The presence of the Cbfb–MYH11 allele in mice was assessed byvery powerful evidence for a dominant negative function
Southern blot hybridization and/or PCR from DNA isolated from tailof Cbfb–MYH11 in the CBF pathway, and demonstrates
snips, yolk sacs, or whole embryos. For the Southern blot analysis,the importance of this fusion gene in the regulation of
10 mg of genomic DNA was digested with NcoI and analyzed using
growth and differentiation of hematopoietic cells. standard procedures. Hybridized blots were exposed to phosphor
The pathogenesis of leukemia is probably a multistep screens (Molecular Dynamics, Sunnyvale, CA), and developed and
process, just as is that for solid tumors. The end result analyzed using PhosphorImager imaging systems (Molecular Dy-
namics). We amplified 50 ng of template DNA by PCR using neo-is theblockage of differentiation and uncontrolled prolif-
specific primers (neo forward 59-AGAGGCTATTCGGCTATGAeration of immature blast cells of various lineages. The
CTG-39, and neo reverse 59-TTCGTCCAGATCATCCTGATC-39). Theresults presented here provide evidence that the fusion
PCR samples were initially denatured at 948C for 2 min, followed
gene CBFB–MYH11, created by chromosome 16 inver- by 30 cycles of amplification (30 s each at 948C, 608C, and 728C),
sion in acute myeloid leukemia subtype M4Eo, is capa- and a final 5 min extension step at 728C. The quality of template
ble of blocking hematopoietic differentiation, an impor- DNA was confirmed in a parallel amplification with primers specific
for sequences from the Trp53 gene (P6.6F 59-ACAGCGTGGTGGtant step in leukemogenesis. Whether this step will lead
Lethality of Cbfb–MYH11 Heterozygous Embryo
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TACCTTATG-39, and P7.1R 59-GGTATACTCAGAGCCGGCCT-39), 5 ml of a-MEM/5% FBS/3% BSA at 48C, and disrupted into single-
cell suspensions by passing through needles. Three cell dilutionsusing the same PCR conditions as described above.
(2 3 103, 1 3 104, and 5 3 104) were plated in the same methylcellu-
lose mix and conditions as described above for yolk sacs culturesCbfb–MYH11 RNA Analysis
(except for liver cells of E12.0 embryos, for which additional erythro-Total RNA was isolated from ES cells and whole embryos using the
poietin was added at 2 U/ml), and colonies were scored at day 7.RNA STAT-60 kit (TEL-TEST, Inc., Friendswood, TX) and reverse-
The scoring of colony-forming unit-erythroid (CFU-E), colony-transcribed with oligo-dT primers (Invitrogen, San Diego, CA) and
forming unit-granulocyte/macrophage (CFU-GM), and colony-form-Superscript II RT reverse transcriptase (GIBCO-BRL, Gaithersburg,
ing unit-granulocyte/erythroid/macrophage/megakaryocyte (CFU-MD) using standard methods, and 1 mg of the RT product was used
GEMM) colonies were performed following Eaves and Lambieas template in each amplification reaction. The presence of the
(1995).Cbfb–MYH11 cDNA was identified using a sense primer that spans
In vitro differentiation experiments of ES cells were performedthe exon 3–4 boundary of the mouse Cbfb gene (mC3/4.1F:
following the procedures as described in Wang et al. (1996a).59-GCAGGCAAGGTATACTTGAAGG-39) and an antisense primer in-
cluded in the human MYH11 cDNA (MHC39A: 59-CTCTTCTCCTCATT
CTGCTC-39). The quality of the reverse-transcribed cDNA was con- Acknowledgments
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